An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Overview of attention for article published in Blood, November 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

policy: 3 policy sources
twitter: 12 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 716 Dimensions

Readers on

mendeley: 443 Mendeley
citeulike: 1 CiteULike

Summary Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 14 X posts from 12 X users, with an upper bound of 95,745 followers.

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era https://t.co/5H0WbyfAxe

03 Jul 2021

Reply Repost Favourite

New risk stratification tool in Diffuse large B cell Lymphoma (DLBCL) in the Rituximab era @DrAnasYounes http://t.co/RR0bapsC1D

17 Feb 2014

Reply Repost Favourite

New risk stratification tool in Diffuse large B cell Lymphoma (DLBCL) in the Rituximab era @DrAnasYounes http://t.co/RR0bapsC1D

17 Feb 2014

Reply Repost Favourite

New risk stratification tool in Diffuse large B cell Lymphoma (DLBCL) in the Rituximab era @DrAnasYounes http://t.co/RR0bapsC1D

17 Feb 2014

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 10 additional X posts.